Login / Signup

Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden.

Bjorn EliassonJan EkelundMervete MiftarajMattis Flyvholm RantheAnn-Charlotte MårdbyJoão Diogo Da Rocha FernandesAnn-Marie Svensson
Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)
After 12 months, 84% of patients were persistent on IDegLira, with improved glycaemic control and reductions in body weight.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • body weight
  • chronic kidney disease
  • type diabetes
  • prognostic factors
  • patient reported outcomes